A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties of NN1250 After Different Routes of Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Insulin degludec (Primary) ; Insulin degludec (Primary) ; Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 19 Nov 2010 Status changed from active, no longer recruiting to completed.
- 31 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.